- ICH GCP
- EU臨床試験登録
最新の試験
EudraCT Number: 2005-003701-91 | Sponsor Protocol Number: INT 27/04 | Start Date: 2004-09-17 | |||||||||||
Sponsor Name: ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: ONCE WEEKLY DOSING OF DARBEPOETIN ALPHA AS PROPHYLACTIC TREATMENT FOR ANEMIA IN ELDERLY CANCER PATIENTS | |||||||||||||
Medical condition: ELDERLY PATIENTS WITH GASTROINTESTINAL AND LUNG CANCER | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000850-22 | Sponsor Protocol Number: 044(2A)SC04030 | Start Date: 2004-09-17 | |||||||||||
Sponsor Name: ANGELINI | |||||||||||||
Full Title: Evaluation of tolerability and analgesic activity of paracetamol 1000 mg+caffeine 130 mg in the treatment of tension-type headache. Randomized, double blind, double-dummy, cross-over study vs. napr... | |||||||||||||
Medical condition: Evaluation of tolerability and analgesic activity in the treatment of tension-type headache | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000137-11 | Sponsor Protocol Number: EMR62202-013 | Start Date: 2004-09-17 | |||||||||||
Sponsor Name: Merck KGaA | |||||||||||||
Full Title: Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor recepto... | |||||||||||||
Medical condition: First-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) FI (Completed) IT (Completed) LT (Completed) EE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001075-20 | Sponsor Protocol Number: FG-506-17-04 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Fujisawa GmbH | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, DOUBLE-DUMMY PLACEBO- CONTROLLED PARALLEL-GROUP MULTIPLE DOSE STUDY OF THE EFFICACY AND SAFETY OF TACROLIMUS INHALATION AEROSOL IN PATIENTS WITH MODERATE P... | |||||||||||||
Medical condition: Moderate persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000406-51 | Sponsor Protocol Number: EMD20001 | Start Date: 2004-09-16 | ||||||
Sponsor Name: GlaxoSmithKline | ||||||||
Full Title: A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment o... | ||||||||
Medical condition: Suspected or Confirmed Gram-negative Severe Sepsis in Adults | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: FI (Completed) ES (Completed) CZ (Completed) LV (Completed) AT (Completed) HU (Completed) DK (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000632-82 | Sponsor Protocol Number: AC-052-333 | Start Date: 2004-09-16 | ||||||
Sponsor Name: Actelion Pharmaceuticals Ltd. | ||||||||
Full Title: Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers | ||||||||
Medical condition: SSc is a multi-system disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin and visceral organs. The pathogenesis of SSc involves immunologic mechanisms vascu... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) IT (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000530-37 | Sponsor Protocol Number: 24978 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Serono International S.A. | |||||||||||||
Full Title: A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjec... | |||||||||||||
Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001662-41 | Sponsor Protocol Number: BAP00154 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Basilea Pharmaceutica Ltd | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections | |||||||||||||
Medical condition: Complicated skin and skin structure infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001730-17 | Sponsor Protocol Number: BAP00248/307 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: A Phase 3, Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001069-17 | Sponsor Protocol Number: CSPI135ZDE04 | Start Date: 2004-09-16 | |||||||||||
Sponsor Name: Novartis Pharma GmbH | |||||||||||||
Full Title: A double-blind, active-controlled, randomized, multicenter, parallel-group 2 day comparison of 1000 mg propyphenazone / 80 mg codeine (applied as two suppositories) combination therapy versus a 100... | |||||||||||||
Medical condition: acute, at least moderate to severe biliary or urogenital pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |